With over 0.49 million Monte Rosa Therapeutics Inc (GLUE) shares trading Friday and a closing price of $5.74 on the day, the dollar volume was approximately $2.84 million. The shares have shown a negative half year performance of -11.83% and its price on 12/22/23 gained nearly 7.29%. Currently, there are 49.32M common shares owned by the public and among those 31.59M shares have been available to trade.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Shares of Monte Rosa Therapeutics Inc (NASDAQ: GLUE) opened at $5.38, up $0.03 from a prior closing price of $5.35. However, the script later moved the day high at 5.94, up 7.29%. The company’s stock has a 5-day price change of 14.80% and -5.44% over the past three months. GLUE shares are trading -24.57% year to date (YTD), with the 12-month market performance down to -31.18% lower. It has a 12-month low price of $2.44 and touched a high of $8.83 over the same period. GLUE has an average intraday trading volume of 300.00K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 42.66%, 58.25%, and 0.63% respectively.
Institutional ownership of Monte Rosa Therapeutics Inc (NASDAQ: GLUE) shares accounts for 68.56% of the company’s 49.32M shares outstanding.
It has a market capitalization of $287.46M and a beta (3y monthly) value of 1.27. The earnings-per-share (ttm) stands at -$2.69. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.20% over the week and 11.08% over the month.
Analysts forecast that Monte Rosa Therapeutics Inc (GLUE) will achieve an EPS of -$0.27 for the current quarter, -$0.65 for the next quarter and -$2.63 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.68 while analysts give the company a high EPS estimate of $0.28. Comparatively, EPS for the current quarter was -$0.63 a year ago. Earnings per share for the fiscal year are expected to decrease by -0.40%, and -13.82% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 8 brokerage firm advisors rate Monte Rosa Therapeutics Inc (GLUE) as a “Strong Buy” at a consensus score of 1.25. Specifically, 7 Wall Street analysts polled rate the stock as a buy, while 1 of the 8 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the GLUE, a number of firms have released research notes about the stock. Wells Fargo stated their Overweight rating for the stock in a research note on January 03, 2023, with the firm’s price target at $18.
